Shreehas Tambe appointed as MD and CEO of Biocon Biologics

Tambe will lead the company in realising its goal of being a global biosimilar leader

Biocon Biologics Ltd (BBL), a subsidiary of Biocon announced that Shreehas Tambe, Deputy CEO of Biocon Biologics, has been appointed as the Managing Director and CEO of the company. Tambe will lead BBL in realising its goal of being a global biosimilar leader.  


Tambe takes over from Dr Arun Chandavarkar, who will continue to serve as a non-Executive, non-Independent Director on the Board of Biocon Biologics.

Kiran Mazumdar-Shaw, Executive Chairperson, Biocon & Biocon Biologics, said, “I am pleased that Tambe is taking on the responsibility of leading Biocon Biologics as MD & CEO at a time when the company is gearing up for global leadership in biosimilars with the closing of the Viatris acquisition. His demonstrated track record of business success and deep technical and operational expertise provide him with proven leadership capabilities to assume this role. Tambe will be aided by a highly experienced Executive Leadership Team in building a future-ready, world-leading biosimilars player and a well-recognized global brand that is committed to impacting global healthcare. I extend my best wishes to him for a successful journey ahead.”

Tambe, said, “As I step into the role of Managing Director and CEO, I am deeply humbled and honoured by the confidence that the Board of Biocon Biologics has reposed in me to lead the company. It has been an absolute privilege to have participated in the evolution of Biocon from an enzyme company to a global biopharmaceutical enterprise. As a company, we have always pushed boundaries, challenged status-quo, and Dared to Dream – Big! The recent acquisition of Viatris’ global biosimilars business, is a game-changing event in our journey. As a fully integrated Biosimilars company, this puts us in a unique position to serve patients across the world. Undoubtedly these are exciting times, and together with an exceptional team, I am looking forward to leading Biocon Biologics in the next phase of growth.”

Mazumdar-Shaw said, “I would like to thank Dr Chandavarkar for his tremendous contributions to the Biocon Group and Biocon Biologics over the past three decades. Dr Chandavarkar has been an integral part of Biocon’s journey since 1990 and came back from retirement to step in as the Managing Director of Biocon Biologics in January 2021. Under his leadership, Biocon Biologics has made rapid strides towards realising its strategic goal of being a global leader in biosimilars. He led the xompany’s recovery from pandemic-related setbacks and steered the organization back onto the path of sustainable growth. I look forward to his active contributions to the BBL Board.”

Dr Chandavarkar, the outgoing MD, Biocon Biologics, said, “It’s been my privilege to have led Biocon and now, Biocon Biologics through many pivotal moments and pioneering achievements over my three-decade association with the company. I wish my successor Shreehas and all my colleagues the very best in continuing the transformation of Biocon Biologics into a leading global biosimilar company with fully integrated capabilities. The greatest satisfaction comes from knowing that we make a positive difference to patients globally, especially in terms of access and affordability.”

As Deputy CEO of Biocon Biologics since March 2021, Tambe has played an important and very effective role in supporting Dr Arun Chandavarkar to steer the company towards sustainable growth and build a strong foundation for the future. Both have also played an integral role in Biocon Biologics’ historic acquisition of Viatris’ global biosimilars business and the strategic alliance with Serum Institute Life Sciences (SILS), which will drive BBL’s future growth and create long-term value for all its stakeholders.

Tambe has been with Biocon since 1997 and has held diverse leadership and operational roles. Over the past 25 years, he has helped build and shape Biocon’s biosimilars business and spearheaded the Group’s strategic capital investments, including its first overseas facility in Malaysia. He has also been instrumental in securing regulatory approvals and enabling the successful launch of several of the Company’s biosimilar assets in global markets such as the US and EU.

Tambe holds a Masters’ degree in Bioprocess Technology from ICT (UDCT), University of Mumbai and has also studied Pharmaceutical Sciences & Technology at the University of Pune. He was conferred the coveted Distinguished Alumnus Award (Professional) by his alma mater, the prestigious ICT, Mumbai, in 2020.


Support us in our endeavor to bring you Advertisement free content.
Choose your options to donate or subscribe.


Related Articles

Back to top button